Litmus test or destination systemic therapy? Trends in referral for surgery after initial systemic therapy in metastatic kidney cancer.

Authors

null

Liam Connor Macleod

University of Washington, Seattle, WA

Liam Connor Macleod , Atreya Dash , George Schade , Scott S. Tykodi , John L. Gore

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Penile, Urethral, and Testicular Cancers; Renal Cell Cancer

Track

Renal Cell Cancer,Penile, Urethral, and Testicular Cancers

Sub Track

Renal Cell Cancer

Citation

J Clin Oncol 35, 2017 (suppl 6S; abstract 502)

DOI

10.1200/JCO.2017.35.6_suppl.502

Abstract #

502

Poster Bd #

F18

Abstract Disclosures

Similar Posters

Poster

2017 Genitourinary Cancers Symposium

Impact of cytoreductive nephretomy on timing of systemic therapy in metastatic kidney cancer.

Impact of cytoreductive nephretomy on timing of systemic therapy in metastatic kidney cancer.

First Author: Liam Connor Macleod

Poster

2022 ASCO Genitourinary Cancers Symposium

Active surveillance in metastatic renal cell carcinoma: A single-center cohort.

Active surveillance in metastatic renal cell carcinoma: A single-center cohort.

First Author: William Schwartzman

Poster

2024 ASCO Genitourinary Cancers Symposium

Efficacy of perioperative pembrolizumab treatment in patients with resectable metastases from kidney cancer: The PE-PE study.

Efficacy of perioperative pembrolizumab treatment in patients with resectable metastases from kidney cancer: The PE-PE study.

First Author: Roberto Iacovelli

Poster

2023 ASCO Genitourinary Cancers Symposium

The survival benefit of metastasectomy for metastatic non-clear cell renal cell carcinoma.

The survival benefit of metastasectomy for metastatic non-clear cell renal cell carcinoma.

First Author: Jindong Dai